Found: 3
Select item for more details and to access through your institution.
A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics.
- Published in:
- Child Psychiatry & Human Development, 2023, v. 54, n. 5, p. 1360, doi. 10.1007/s10578-022-01328-5
- By:
- Publication type:
- Article
Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).
- Published in:
- Journal of Autism & Developmental Disorders, 2021, v. 51, n. 8, p. 2959, doi. 10.1007/s10803-020-04709-8
- By:
- Publication type:
- Article